<DOC>
	<DOCNO>NCT01110135</DOCNO>
	<brief_summary>This phase II trial study well give bendamustine hydrochloride , etoposide , dexamethasone , filgrastim together peripheral stem cell mobilization work treat patient refractory recurrent lymphoma multiple myeloma . Giving chemotherapy , bendamustine hydrochloride , etoposide , dexamethasone , peripheral stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , filgrastim , certain chemotherapy drug help stem cell move bone marrow blood collect store</brief_summary>
	<brief_title>Bendamustine Hydrochloride , Etoposide , Dexamethasone , Filgrastim For Peripheral Blood Stem Cell Mobilization Treating Patients With Refractory Recurrent Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate frequency bendamustine ( bendamustine hydrochloride ) combine GCSF ( filgrastim ) dexamethasone successfully mobilize peripheral blood stem cell ( PBSCs ) ( determine collect minimum 2 x 10^6 cluster differentiation ( CD ) 34+/kg ) . SECONDARY OBJECTIVES : I . To evaluate response rate bendamustine diagnosis use establish disease-specific response criterion . II . To examine number apheresis cycle require collect minimum 2 x 10^6 CD34+ cells/kg ideally &gt; = 5 x 10^6 CD34+ cells/kg ( achievable ) . III . To assess impact bendamustine B T-lymphocyte population peripheral blood ( CD20+ cell , natural killer [ NK ] cell , CD4+25+ foxP3- regulatory cell , CD8 cell ) . OUTLINE : Patients receive bendamustine hydrochloride intravenously ( IV ) 30-60 minute day 1 2 , etoposide IV 60-240 minute day 1-3 , dexamethasone orally ( PO ) day 1-4 , filgrastim subcutaneously ( SC ) begin day 5 continue peripheral blood stem cell collection complete . Patients undergo leukapheresis daily minimum 3 day &gt; 5 x 10^6 CD34+/kg collect . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must relapse primary refractory lymphoid malignancy ( include Bcell , Tcell , Hodgkin lymphoma ) , multiple myeloma ; transplant eligible diagnosis ( e.g . germ cell tumor ) include principal investigator ( PI ) approval World Health Organization ( WHO ) classification patient ' malignancy must provide Patients lymphoid malignancy must compute tomography ( CT ) chest , abdomen , pelvis within six week enrollment ; patient evidence lymphadenopathy neck must CT neck Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelets &gt; = 100,000/mm^3 ( without transfusion growth factor support ) Creatinine clearance ( CrCl ) great 50/ml per minute ( test must perform within 28 day prior registration ) Total bilirubin &lt; 1.5 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 time upper limit normal All patient must inform investigational nature study give write consent accordance institutional federal guideline Adequate venous access plan place apheresis procedure Three few prior myelotoxic treatment regimen ( specific regimen include ifosfamide , carboplatin etoposide [ ICE ] ; cisplatin , cytarabine , dexamethasone [ DHAP ] ; methotrexate [ MTX ] /highdose cytarabine [ HiDAC ] ; cyclophosphamide , vincristine , doxorubicin , dexamethasone [ hyperCVAD ] ; bortezomib , thalidomide , dexamethasone 4day continuous infusion cisplatin , doxorubicin , cyclophosphamide , etoposide [ VTDPACE ] ) Patients know positive human immunodeficiency virus ( HIV ) , infectious hepatitis type B C Pregnant nursing woman ; men woman reproductive potential may participate unless agree use effective contraceptive method Greater six prior cycle lenalidomide therapy Patients previously demonstrate resistance bendamustine therapy ( i.e . response progression w/in 6 month ) Fludarabine nucleoside analog ( except gemcitabine cytarabine ) therapy within 24 month registration ; patient limited exposure fludarabine/other nucleoside analog therapy within 24 month may consider eligible review approval PI CoPI prior study entry Symptomatic cardiopulmonary disease Prior autologous allogeneic transplantation Prior radioimmunotherapy within 12 week registration Prior fail ( &lt; 5 x 10^6 CD34/kg ) PBSC collection due inability mobilize stem cell Prior pelvic spinal irradiation Previous systemic chemotherapy/immunotherapy within 3 week study entry Concurrent use anticancer agent experimental treatment Known allergy intolerance bendamustine , mannitol , GCSF dexamethasone More 3 cycle myelotoxic salvage chemotherapy within past 4 month ( specific regimen include ICE , DHAP , MTX/HiDAC , hyperCVAD , VTDPACE )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>